Model Informed Drug Development Archives

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

Video

MIDD is Transforming Drug Development

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You wanna see somebody actually have access to the drug that needs it. And I'm…

Certara2026 年 5 月 21 日

Guide

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

Certara2026 年 5 月 12 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Certara2026 年 5 月 8 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 23 日 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

Certara2026 年 4 月 23 日

模型引导的药物开发

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

MIDD is Transforming Drug Development

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Minimize risk when preparing for hepatic impairment studies

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Top 10 Benefits of Simcyp® Simulator for Drug Development

订阅时事通讯

快捷链接

解决方案

联系我们